# EDGAR Filing Document

**Accession Number:** 0001770787
**File Stem:** 0001628280-26-032073
**Filing Date:** 2026-5
**Character Count:** 18042
**Document Hash:** 44c44118c99c27fc08385fa637bcc6f9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-032073.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001628280-26-032073

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260507

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 10x Genomics, Inc.
- **CENTRAL INDEX KEY:** 0001770787
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455614458
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39035
- **FILM NUMBER:** 26953013

**BUSINESS ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588
- **BUSINESS PHONE:** (925) 401-7300

**MAIL ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 10X Genomics, Inc.
- **DATE OF NAME CHANGE:** 20190315

?xml version='1.0' encoding='ASCII'? txg-20260507

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**______________________**

**FORM 8-K**

**______________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 7, 2026**

![Logo-10x.jpg](txg-20260507_g1.jpg)

**10x Genomics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39035** | **45-5614458** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**6230 Stoneridge Mall Road**

**Pleasanton, California 94588**

**(925) 401-7300**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**___________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol** | **Name of each exchange**<br>**on which registered** |
| **Class A common stock, par value $0.00001 per share** | **TXG** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On May 7, 2026, 10x Genomics, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;(d)*Exhibits.*

---

| | |
|:---|:---|
| Exhibit No. | Description of Exhibits |
| 99.1 | <u>[Press Release dated](txg-20260507xexx991.htm)[May 7, 2026](txg-20260507xexx991.htm)[.](txg-20260507xexx991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | 10x Genomics, Inc. | 10x Genomics, Inc. |
| | By: | /s/ Randy Wu |
| | Name: | Randy Wu |
| | Title: | General Counsel and Secretary |
| Date: May 7, 2026 |  |  |

---

## Exhibit 99.1

**Exhibit 99.1**

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

**10x Genomics Reports First Quarter 2026 Financial Results**

**PLEASANTON, Calif.** May 7, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.

**Recent Updates** 

&nbsp;&nbsp;&nbsp;&nbsp;• Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;• Launched Atera, a new platform to redefine how biology is measured and understood. Atera was engineered to deliver spatial whole-transcriptome analysis with single-cell sensitivity at unprecedented scale. The Company expects to start shipping Atera in the second half of 2026.

&nbsp;&nbsp;&nbsp;&nbsp;• Announced a partnership with Bioptimus, a global AI biotech company, to launch STELA, a multinational spatial data generation initiative to create foundational datasets connecting underlying biology with disease outcomes. The initiative is starting this effort on our Xenium platform and plans to expand to Atera over time.

&nbsp;&nbsp;&nbsp;&nbsp;• Ended the first quarter of 2026 with cash and cash equivalents and marketable securities of $539.8 million, representing a $112.9 million increase from March 31, 2025.

"We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The biggest highlight is our recent launch of Atera, which represents the most significant product introduction in our history. We are extremely encouraged by the extraordinary early customer response."

**First Quarter 2026 Financial Results**

Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025. Excluding $16.8 million related to a patent litigation settlement recognized in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.

Gross margin was 70% for the first quarter of 2026, as compared to 68% for the corresponding prior year period. The increase in gross margin was primarily due to lower warranty costs and lower inventory write-downs, partially offset by a decrease in license and royalty revenue reflecting a non-recurring royalty benefit recognized in the first quarter of 2025.

Operating expenses were $123.2 million for the first quarter of 2026, a 15% decrease from $144.8 million for the corresponding prior year period. The decrease was primarily driven by lower outside legal expenses and personnel expenses, partially offset by a non-recurring gain on settlement of $9.2 million recognized in the first quarter of 2025.

Operating loss was $17.0 million for the first quarter of 2026, as compared to operating loss of $39.3 million for the corresponding prior year period.

Net loss was $13.5 million for the first quarter of 2026, as compared to a net loss of $34.4 million for the corresponding prior year period.

Cash and cash equivalents and marketable securities were $539.8 million as of March 31, 2026.

**2026 Financial Guidance** 

10x Genomics is maintaining its full year 2026 revenue guidance of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in 2025, this represents 0% to 4% growth over full year 2025.

------

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

**Webcast and Conference Call Information**

10x Genomics will host a conference call to discuss the first quarter 2026 financial results, business developments and outlook after market close on Thursday, May 7, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at <u>http://investors.10xgenomics.com</u>. The webcast will be archived and available for replay at least 45 days after the event.

**About 10x Genomics**

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit <u>10xgenomics.com</u> or connect with us on <u>LinkedIn</u>, <u>X</u>, <u>Facebook</u>, <u>Bluesky</u> or <u>YouTube</u>.

**Forward Looking Statements**

**Disclosure Information**

10x Genomics uses filings with the Securities and Exchange Commission, its website (<u>www.10xgenomics.com</u>), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

**Contacts**

Investors: <u>investors@10xgenomics.com</u>

Media: <u>media@10xgenomics.com</u>

------

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

**10x Genomics, Inc.**

**Condensed Consolidated Statements of Operations**

*(Unaudited)*

*(In thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Products and services revenue | $149896 | $137823 |
| License and royalty revenue | 947 | 17060 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue <sup>(1)</sup> | 150843 | 154883 |
| Cost of products and services revenue <sup>(2)</sup> | 44665 | 49438 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 106178 | 105445 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development <sup>(2)</sup> | 56847 | 64245 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative <sup>(2)</sup> | 66377 | 89728 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on settlement |  | (9200) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 123224 | 144773 |
| Loss from operations | (17046) | (39328) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 5014 | 3686 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | (815) | 2136 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income | 4199 | 5822 |
| Loss before provision for income taxes | (12847) | (33506) |
| Provision for income taxes | 623 | 852 |
| Net loss | $(13470) | $(34358) |
| Net loss per share, basic and diluted | $(0.10) | $(0.28) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 128291153 | 122606091 |

---

__________________________

<sup>(1)&nbsp;&nbsp;&nbsp;&nbsp;</sup>The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium and Xenium products:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Instruments** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Single Cell | $5223 | $5913 |
| &nbsp;&nbsp;&nbsp;&nbsp;Spatial | 6039 | 8902 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total instruments revenue** | 11262 | 14815 |
| **Consumables** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Single Cell | 88894 | 84109 |
| &nbsp;&nbsp;&nbsp;&nbsp;Spatial | 40907 | 31247 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total consumables revenue** | 129801 | 115356 |
| **Services** | 8833 | 7652 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Products and services revenue** | 149896 | 137823 |
| **License and royalty revenue** | 947 | 17060 |
| **Total revenue** | $150843 | $154883 |

---

------

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

<sup>(1)</sup> &nbsp;&nbsp;&nbsp;&nbsp;The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Americas** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United States<sup>\*</sup> | $76693 | $86818 |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas (excluding United States) | 3406 | 3752 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Americas** | 80099 | 90570 |
| **Europe, Middle East and Africa** | 36852 | 31895 |
| **Asia-Pacific** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;China | 15837 | 16883 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia-Pacific (excluding China) | 18055 | 15535 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Asia-Pacific** | 33892 | 32418 |
| **Total revenue** | $150843 | $154883 |

---

\* Includes license and royalty revenue.

<sup>(2)&nbsp;&nbsp;&nbsp;&nbsp;</sup>Includes stock-based compensation expense as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| **(in thousands)** | **2026** | **2025** |
| Cost of revenue | $1918 | $2481 |
| Research and development | 10695 | 14106 |
| Selling, general and administrative | 10029 | 14489 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation expense | $22642 | $31076 |

---

------

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

**10x Genomics, Inc.**

**Condensed Consolidated Balance Sheets**

*(Unaudited)*

*(In thousands)*

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $490285 | $473966 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 49563 | 49443 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 39031 | 47013 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other receivables | 17106 | 35480 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 53487 | 56341 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 20261 | 22208 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 669733 | 684451 |
| Property and equipment, net | 220591 | 226711 |
| Operating lease right-of-use assets | 58390 | 60450 |
| Goodwill | 4511 | 4511 |
| Intangible assets, net | 59910 | 62329 |
| Other noncurrent assets | 2624 | 2913 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1015759 | $1041365 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $17425 | $12733 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation and related benefits | 21506 | 42500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 33680 | 39971 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 24342 | 23902 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 11330 | 10985 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contingent consideration, current | 5315 | 23363 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 113598 | 153454 |
| Contingent consideration, noncurrent | 1222 | 1237 |
| Operating lease liabilities, noncurrent | 70059 | 73376 |
| Deferred revenue, noncurrent | 10138 | 10501 |
| Other noncurrent liabilities | 6418 | 6471 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 201435 | 245039 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock | 2 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 2338269 | 2306690 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (1524061) | (1510591) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 114 | 225 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 814324 | 796326 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1015759 | $1041365 |

---